Skip to main content
Clinical Trials/NCT04014140
NCT04014140
Recruiting
Not Applicable

Long-term Graft Patency Outcomes of LIMA-LAD Post-CABG Surgery Based on iFR Measurements.

Prakash Punjabi1 site in 1 country100 target enrollmentApril 25, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ischaemic Heart Disease
Sponsor
Prakash Punjabi
Enrollment
100
Locations
1
Primary Endpoint
Graft patency
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The expected outcome of better and improved patency of bypass grafts and its direct relation to pre-operative iFR measurements of stenosis as compared to direct visual physiology of stenosis in the coronary angiogram.

To establish the correlation between the use of intracoronary physiology and improved graft patency at 12 months for patients undergoing CABG surgery.

It is a minimum of 28 and a maximum of 100 patients single-centre proof or concept/ observational study/ pilot study.

Detailed Description

Patients suffering from coronary artery disease undergo coronary artery bypass grafting surgery (CABG) as the standard of care. The selection of which vessels to bypass is usually at the discretion of the surgeon forming an opinion based on the pre-operative angiographic imaging. Intra-coronary physiology (iFR measurements) is more accurate to determine the level of damage to the coronary arteries; however, currently it is not used for CABG pre-assessment, but only for percutaneous intervention also known as stenting as it has been shown to improve outcomes. Although, the use of intracoronary physiology has not been extensively studied or validated in patients undergoing CABG. Patients with multi-vessel coronary artery disease (CAD) who are planned for surgical revascularization with coronary artery bypass grafting (CABG), will have iFR measurement taken during invasive coronary angiography as part of standard care, they will undergo CABG and will have echocardiography at 3 months and computed tomography coronary angiography (CTCA) at 12 months. Early graft failure will be assessed by the presentation of any clinical symptoms, major adverse cardiovascular and cerebrovascular events (MACCE) and echocardiography at 3 months. The endpoint will be graft patency as assessed by CT coronary angiography at 12 months. Anticipated recruitment is 12-24 months. Follow-up with echocardiography at 3 months and a CTCA at 12 months. Quality of Life questionnaire will be completed by the patient at 3 and 12 months during the follow-up appointment. Patients will continue on optimal medical therapy. Clinic visit and quality of life scale questionnaires will be recorded at 3 and 12 months and echocardiography will be assessed at 3 months. Graft patency at 12 months will be assessed with a CT coronary angiography.

Registry
clinicaltrials.gov
Start Date
April 25, 2022
End Date
August 31, 2026
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Prakash Punjabi
Responsible Party
Sponsor Investigator
Principal Investigator

Prakash Punjabi

Consultant Cardiothoracic Surgeon

Imperial College Healthcare NHS Trust

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Graft patency

Time Frame: 12 months

The primary endpoint will be graft patency as assessed by CT coronary angiography at 12 months.

Secondary Outcomes

  • Incident of Death (cardiovascular)(12 months)
  • Composite of MACE (MI, Death, stroke, repeat revascularisation)(12 months)
  • Incidence of Myocardial infarction(12 months)
  • Incidence of Stroke(12 months)
  • Left ventricular function at 3 months with an echocardiography(3 months)
  • Quality of Life Questionnaire(3 and 12 months)
  • Any episode of reintervention(12 months)
  • Incidence of Death (all-cause)(12 months)

Study Sites (1)

Loading locations...

Similar Trials